MORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo Bio, a clinical-stage biopharmaceutical company developing first-of-its-kind medicines targeting the root cause of hard-to-treat diseases, today announced that Steve Butts, Co-founder and Chief Executive Officer, and Joel Raskin, Chief Medical Officer will participate in a virtual fireside chat discussing forvisirvat, the company’s novel potential treatment for major depressive disorder, at the Piper Sandler Virtual CNS Symposium on Friday, August 14th
Arrivo Bio to Participate in Fireside Chat at the Piper Sandler Virtual CNS Symposium
